Obese youths with leukemia more likely to have persistent disease

October 27, 2014

Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the time of their diagnosis with ALL to determine if body mass index (BMI) impacted response to initial chemotherapy. This response to initial chemotherapy (or induction therapy) is measured by the absence of leukemia cells in the bone marrow. Called minimal residual disease (MRD), in which residual leukemia cells cannot be seen under microscope but can be detected by more sensitive methods, it is among the strongest predictors of long-term survival and disease recurrence. As reported in First Edition of the journal Blood on October 27, following induction chemotherapy, obese patients were more than twice as likely to have minimal residual disease, than non-obese patients.

"Induction chemotherapy provides a patient's best chance for remission or a cure," said principal investigator Steven Mittelman, MD, PhD, of The Saban Research Institute of Children's Hospital Los Angeles. "Our findings indicate that a patient's obesity negatively impacts the ability of chemotherapy to kill leukemia cells, reducing the odds of survival."

The study looked at 198 patients, diagnosed with ALL and between the ages of 1 and 21 years. Each patient's BMI was converted to a percentile and classified according to CDC thresholds for overweight (85 to 94%) and obese (greater than 95%). Patients at less than 85% BMI were considered "lean". About one-third of the patients were obese or overweight at the time of diagnosis.

MRD was determined by testing of bone marrow specimens taken at the end of induction therapy, and patients were followed for two to five years from the time of diagnosis. The investigators found that lean patients with minimal residual disease had similar outcomes to obese patients without evidence of residual disease. Obese patients with residual disease had the worst outcomes. Additionally, although nearly a quarter of the patients initially deemed "lean" gained weight and become obese during the first month of treatment, these patients still showed similar outcomes to those who remained lean.

"In addition to increasing a patient's likelihood of having persistent disease following treatment, obesity appears to add a risk factor that changes the interaction between chemotherapy and residual leukemia cells," said Hisham Abdel-Azim, MD, of The Saban Research Institute of Children's Hospital Los Angeles and co-lead investigator on the study. Abdel-Azim also explained that the investigators were able to examine this interaction in a large number of patients because CHLA had established MRD testing and made it available to all patients before it became widely used as the of standard of care.

Findings from this study offer new avenues for investigation that include modifying chemotherapy regimens for obese patients and working to change a patient's weight status beginning at the time of diagnosis.
Etan Orgel is first author on this study and additional contributors include Jonathan Tucci, Jemily Malvar, Richard Sposto, Cecilia H. Fu, David R. Freyer of Children's Hospital Los Angeles and Waseem Alhushki of Children's Specialty Centers of Nevada.

Funding for the study was provided by a Translational Research Program grant from the Leukemia and Lymphoma Society.

About Children's Hospital Los Angeles

Children's Hospital Los Angeles has been named the best children's hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California.

For more information, visit CHLA.org and follow us on ResearCHLAblog.org.

Media Contact: Ellin Kavanagh, ekavanagh@chla.usc.edu, (323) 361-1812

Children's Hospital Los Angeles

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.